CLINICAL TRIALS PROFILE FOR DROSPIRENONE; ESTRADIOL
✉ Email this page to a colleague
All Clinical Trials for DROSPIRENONE; ESTRADIOL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00102141 ↗ | Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women | Completed | Bayer | Phase 3 | 2004-04-01 | The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension. |
| NCT00356447 ↗ | Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. | Completed | Bayer | Phase 3 | 2006-05-01 | The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints. |
| NCT00413062 ↗ | Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-06-01 | The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years. |
| NCT00420342 ↗ | Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension | Completed | Bayer | Phase 2 | 2007-01-01 | The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension. |
| NCT00446199 ↗ | Low-dose Hormone Therapy for Relief of Vasomotor Symptoms | Completed | Bayer | Phase 3 | 2007-03-01 | The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks. |
| NCT00511199 ↗ | Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-05-01 | The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years. |
| NCT00511433 ↗ | Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-10-01 | The primary purpose of this study is to evaluate the effects of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) on ovarian function. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DROSPIRENONE; ESTRADIOL
Condition Name
Clinical Trial Locations for DROSPIRENONE; ESTRADIOL
Trials by Country
Clinical Trial Progress for DROSPIRENONE; ESTRADIOL
Clinical Trial Phase
Clinical Trial Sponsors for DROSPIRENONE; ESTRADIOL
Sponsor Name
